Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 6/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 6/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 6/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908746 | 0.95 | PER2 (0.36) | PER2CRY1CRY2 | |
| SCHEMBL12384372 | 0.89 | PER2 (0.38) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL17575508 | 0.79 | PSEN1 (0.33) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL1753836 | 0.77 | ALOX5 (0.35) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL12228957 | 0.76 | PER2 (0.43) | PER2CRY1CRY2 | |
| SCHEMBL728955 | 0.76 | PER2 (0.33) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL1486529 | 0.75 | PER2 (0.33) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL17556101 | 0.75 | PER2 (0.33) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL28527867 | 0.75 | PER2 (0.36) | PER2CRY1CRY2PDCD1CD274 | |
| SCHEMBL17574698 | 0.74 | PSEN1 (0.40) | PER2CRY1CRY2PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | PER2 2755/4885CRY1 3756/4885CRY2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.